Table 1 Demographic and clinical details

From: Chronic adaptive deep brain stimulation for Parkinson’s disease: clinical outcomes and programming strategies

        

STN left

STN right

   

#

Age (years)

Sex

Disease duration (years)

Time since surgery (years)

MDS UPDRS III Med OFF Pre-surgery

MDS UPDRS III Med OFF Stim ON 12-months Post-surgery

Chief complaint

Stimulation amplitude limits (mA)

LFP thresholds (µVp)

Beta sensing peak (Hz)

Stimulation amplitude limits (mA)

LFP thresholds (µVp)

Beta sensing peak (Hz)

Concluded aDBS setup

Stayed on aDBS

aDBS sessions (n)

1

74

F

14

4

42

28

Dyskinesia

1.2–1.8

105–270

29.30

1.2–1.8

Unilateral

Unilateral

Yes

Yes

5

2

68

F

10

4

68

20

Dyskinesia

1.8–2.2

Unilateral

Unilateral

1.1–1.7

200–225

17.58

Yes

Yes

13

3

66

F

10

2

50

16

Tremor

1.8–2.8

1725–2575

21.48

2.2–2.8

500–1000

21.48

Yes

Yes

7

4

42

M

17

2

90

42

Tremor

2.1– 2.5

Unilateral

Unilateral

2.1–2.5

320–720

19.53

Yes

Yes

4

5

44

M

12

2

30

32

Peak-dose dystonia

1.4–2

250–700

19.53

2.1–2.4

Unilateral

Unilateral

Yes

Yes

10

6

62

M

17

3

55

20a

Gait impairment

2.4–2.7

100–280

26.37

2 - 2.5

220–400

25.39

Yes

No

7

7

64

M

19

2

71

61

Fine motor control

2.8–3.6

2970–3160

12.70

2.8 - 3.6

700–1100

14.65

No

No

4

8

66

M

14

1

72

16a

Dyskinesia

2.8–3.5

550–750

20.51

2.8 - 3.5

650–950

21.48

Yes

Yes

9

  1. MDS UPDRS III Movement Disorders Society sponsored version of the Unified Parkinson’s disease Rating Scale Part III, LFP Local field potentials, STN Subthalamic nucleus, aDBS adaptive deep brain stimulation.
  2. aMedication ON.